Post-market data and pharmacovigilance for similar biologics MCQs With Answer

Introduction

This quiz set focuses on post-market data and pharmacovigilance specifically for similar biologics (biosimilars), tailored for M.Pharm students studying Regulatory Aspects of Herbal and Biologicals (MRA202T). It covers regulatory expectations for safety monitoring, risk management plans, signal detection, immunogenicity surveillance, traceability, and reporting timelines used by major agencies (e.g., EMA, WHO, CDSCO). Questions probe practical and conceptual aspects — from designing post-authorization safety studies and interpreting Periodic Safety Update Reports to managing adverse event causality and batch-level traceability. These MCQs aim to deepen understanding of how post-market pharmacovigilance ensures ongoing patient safety for similar biologics.

Q1. What is the primary focus of post-market pharmacovigilance for similar biologics?

• To optimize manufacturing yields and reduce production cost
• To monitor and manage the safety profile, including immunogenicity, after authorization
• To perform preclinical toxicology studies not completed before approval
• To determine final pricing and reimbursement strategies

Correct Answer: To monitor and manage the safety profile, including immunogenicity, after authorization

Q2. Which document most commonly describes planned post-authorization safety activities for a biosimilar?

• Common Technical Document (CTD) Module 3
• Risk Management Plan (RMP)
• Biologic License Application (BLA)
• Good Manufacturing Practice (GMP) certificate

Correct Answer: Risk Management Plan (RMP)

Q3. Which of the following is the best definition of “traceability” in the pharmacovigilance of similar biologics?

• Tracking patient reimbursement claims for a biologic
• Ability to identify the specific product brand name and batch number associated with an adverse event
• Following the supply chain logistics to prevent theft
• Monitoring environmental impact of biologic manufacturing

Correct Answer: Ability to identify the specific product brand name and batch number associated with an adverse event

Q4. For a serious unexpected adverse event (SUSAR) occurring in a clinical trial, what is the typical regulatory reporting timeline to authorities?

• Within 7 calendar days for fatal/life-threatening SUSARs, then 8 additional days for follow-up
• Within 30 days for all SUSARs
• No reporting required until the end of the study
• Only report SUSARs annually in aggregate

Correct Answer: Within 7 calendar days for fatal/life-threatening SUSARs, then 8 additional days for follow-up

Q5. Which periodic safety report compiles global safety data for a medicinal product and is often required post-authorization?

• Investigator’s Brochure (IB)
• Periodic Safety Update Report (PSUR) / Periodic Benefit-Risk Evaluation Report (PBRER)
• Batch Release Certificate
• Certificate of Pharmaceutical Product (CPP)

Correct Answer: Periodic Safety Update Report (PSUR) / Periodic Benefit-Risk Evaluation Report (PBRER)

Q6. Why is immunogenicity monitoring particularly important for similar biologics after market approval?

• Because biosimilars are chemically identical to the reference product
• Because small structural or process differences can elicit immune responses affecting safety and efficacy
• Because immunogenicity determines cold chain requirements
• Because it is only a concern during manufacturing validation

Correct Answer: Because small structural or process differences can elicit immune responses affecting safety and efficacy

Q7. Which regulatory concept refers to continuous scanning of safety data to detect new or changing risks for a biologic?

• Signal detection
• Biosimilarity assessment
• Comparability exercise
• Marketing authorization renewal

Correct Answer: Signal detection

Q8. What type of post-authorization study is commonly used to assess rare adverse events or long-term outcomes for biosimilars?

• Phase I single-dose pharmacokinetic study
• Post-Authorization Safety Study (PASS), including observational cohort or registry studies
• In vitro binding assays
• Stability studies at accelerated conditions

Correct Answer: Post-Authorization Safety Study (PASS), including observational cohort or registry studies

Q9. In pharmacovigilance terminology, what is a “signal”?

• A confirmed causal relationship between a product and an adverse event
• Data or information suggesting a new potentially causal association between an intervention and an event that warrants further investigation
• A marketing claim approved by the authority
• A batch-level manufacturing deviation

Correct Answer: Data or information suggesting a new potentially causal association between an intervention and an event that warrants further investigation

Q10. Which element is essential in an adverse event report for a biosimilar to support traceability?

• Manufacturer’s corporate headquarters address
• Batch/lot number or device identifier for the administered product
• Full detailed manufacturing process description
• Clinical trial randomization code

Correct Answer: Batch/lot number or device identifier for the administered product

Q11. Which international body has provided guidelines specifically addressing pharmacovigilance for biologicals and biosimilars?

• World Health Organization (WHO)
• International Organization for Standardization (ISO)
• Food and Agriculture Organization (FAO)
• International Monetary Fund (IMF)

Correct Answer: World Health Organization (WHO)

Q12. What is the main goal of a risk minimization plan for a biosimilar included in the RMP?

• To accelerate product uptake in the market
• To describe measures to prevent or reduce the occurrence and severity of adverse reactions and to inform safe use
• To detail manufacturing cost-saving strategies
• To outline plans for patent extension

Correct Answer: To describe measures to prevent or reduce the occurrence and severity of adverse reactions and to inform safe use

Q13. Which of the following best describes “interchangeability” in the context of biosimilars?

• Identification of identical batch numbers between two products
• Regulatory designation allowing substitution at pharmacy level without prescriber intervention in some jurisdictions, often requiring additional evidence
• Manufacturer’s right to change formulation without notice
• Automatic global recognition of any biosimilar as identical to the reference product

Correct Answer: Regulatory designation allowing substitution at pharmacy level without prescriber intervention in some jurisdictions, often requiring additional evidence

Q14. What is the Pharmacovigilance System Master File (PSMF) primarily intended to document?

• Clinical trial statistical analysis plans
• The structure and functioning of the marketing authorization holder’s pharmacovigilance system
• Product labeling translations
• Commercial distribution contracts

Correct Answer: The structure and functioning of the marketing authorization holder’s pharmacovigilance system

Q15. Which statistical or methodological approach is commonly used for detecting disproportional reporting of adverse events in spontaneous reporting databases?

• Non-compartmental PK modeling
• Disproportionality analysis (e.g., reporting odds ratio, proportional reporting ratio)
• Cluster-randomized trial design
• Accelerated stability modeling

Correct Answer: Disproportionality analysis (e.g., reporting odds ratio, proportional reporting ratio)

Q16. When evaluating an immunogenicity-related safety signal for a biosimilar, which additional information is most critical?

• Patient’s diet during treatment
• Characterization of anti-drug antibodies (neutralizing vs non-neutralizing), timing relative to dosing, and clinical impact (loss of efficacy or hypersensitivity)
• Country of origin of the raw materials
• Anticipated market share estimates

Correct Answer: Characterization of anti-drug antibodies (neutralizing vs non-neutralizing), timing relative to dosing, and clinical impact (loss of efficacy or hypersensitivity)

Q17. Which regulatory action is commonly taken if a post-marketing evaluation identifies a clinically important new risk for a biologic?

• Immediate withdrawal of marketing authorization without communication
• Updating product labeling, implementing additional risk minimization activities, or restricting use pending further data
• Transferring responsibility to the pharmacists union
• Changing the product’s storage temperature requirements only

Correct Answer: Updating product labeling, implementing additional risk minimization activities, or restricting use pending further data

Q18. For biosimilars, why is interchangeability or switching studies sometimes included in post-authorization monitoring?

• To evaluate commercial competitiveness against generics
• To assess potential clinical effects (safety, efficacy, immunogenicity) when patients switch between products in real-world practice
• To validate cold chain logistics
• To determine the difference in manufacturing costs after launch

Correct Answer: To assess potential clinical effects (safety, efficacy, immunogenicity) when patients switch between products in real-world practice

Q19. Which data source is least likely to be useful for routine signal detection of biologics?

• Spontaneous adverse event reporting databases
• Electronic health records and claims databases
• Active disease registries specific to the therapeutic area
• Product marketing brochures

Correct Answer: Product marketing brochures

Q20. Which element improves the quality of post-market adverse event reporting for similar biologics in clinical practice?

• Reporting only serious events and ignoring non-serious ones
• Education of healthcare professionals on including product name, batch number, patient history, and clinical outcome in reports
• Delaying reports until annual review meetings
• Using only aggregate sales data to infer safety

Correct Answer: Education of healthcare professionals on including product name, batch number, patient history, and clinical outcome in reports

Download